September 12, 2024 01:33 PM EDT

FDA should embrace new ways of evaluating rare disease drugs, report argues

Jared Whitlock

Features Editor

To increase the pace of rare disease drug approvals, the FDA should embrace nontraditional data, deploy new forms of analysis and be more open about …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

FDA should embrace new ways of evaluating rare disease drugs, report argues

Jared Whitlock

Features Editor

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Bad trip: How culture conflict and a need for cash nearly broke Lykos

Cigna sues FTC, calling for withdrawal of 'biased, erroneous' PBM report

Novartis’ Kisqali snags FDA approval to reduce recurrence in patients with early forms of breast cancer

After landing a key win in a common cancer condition, Pfizer faces a big test in Phase 3

23andMe heads to ESMO to tout its two clinical-stage drugs after scrapping discovery team

Breaking down silos with a new quantitative approach to drug development

FDA should em­brace new ways of eval­u­at­ing rare dis­ease drugs, re­port ar­gues

Features Editor

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

FDA should embrace new ways of evaluating rare disease drugs, report argues